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We feel compelled to point out a few inconsistencies in new reports 
surfacing to support the use of remdesivir in the COVID-19 crisis.
The National Institute of Allergy and Infectious Diseases (NIAID) 
in the USA, which oversaw the trial of remdesivir in the Adaptive 
COVID-19 Treatment Trial (ACTT), reported that patients on 
the drug (developed by Gilead Sciences) had a 31% faster time to 
recovery than those on a placebo.[1] Mortality was reduced, but the 
decrease did not reach statistical significance. The ACTT involved 
1 063 patients and is yet to be published. A press release by the NIAID 
on 29 April 2020 revealed the results from an interim analysis by 
the data and safety board overseeing the trial. No further details or 
results are available, although they are due soon (ClinicalTrials.gov 
identifier NCT04280705). The US Food and Drug Administration 
(FDA) fast-tracked registration of remdesivir for use as treatment for 
COVID-19, based on this action of the NIAID, and which we believe, 
lacks transparency.
In a study published in The Lancet,[2] remdesivir use was not 
associated with a difference in time to clinical improvement (hazard 
ratio (HR) 1.23; 95% confidence interval (CI) 0.87 - 1.75). Although 
not statistically significant, patients with a symptom duration of 
≤10 days receiving remdesivir had a numerically faster time to 
clinical improvement than those receiving placebo (HR 1.52; 95% 
CI 0.95 - 2.43).[2]
Clearly in these difficult times we are exploring all options for 
therapy. However, lack of evidence is not the same as evidence of 
lack.
Therapies for CoVID-19
Emerging literature has so far suggested that COVID-19-positive 
patients with mild disease should receive symptomatic treatment, 
which may include paracetamol and possibly vitamin D 50 000 units 
weekly or 4 000 units daily.[3] There are limited data available on 
effective treatment strategies for more severe disease.
Antiviral therapy
Antiviral therapy may be of value, although a recent trial showed that 
lopinavir/ritonavir used as a single agent was unsuccessful in efficacy 
and efficiency.[4] There are numerous other ongoing studies utilising 
a variety of antiviral agents.[5]
Chloroquine (with or without azithromycin) is another potential 
antiviral agent. Studies are still emerging to validate its use or negate 




A systematic review of observational studies of corticosteroids 
administered to patients with COVID-19 reported no survival 
benefit, but rather possible harm.[6] However, benefit has been 
observed in a recent study of patients with pulmonary infiltrates, and 
corticosteroids may have a role in preventing progression to a hyper-
inflammatory state.[7]
Tocilizumab
Tocilizumab is a humanised monoclonal antibody that has been 
approved for treatment of patients with rheumatoid arthritis. It 
inhibits interleukin 6 (IL-6), which is secreted by monocytes and 
macrophages. IL-6 is significantly increased in patients who have 
developed the ‘cytokine storm’ described in severe COVID-19.[8]
A small study from China looked at a single dose of 400 mg (1 patient 
received a second dose) in 21 patients. All were confirmed cases with 
markedly elevated IL-6. All patients improved over the next few days 
with an initial resolution of fever, improvement in gas exchange, 
normalisation of C-reactive protein by day 5 and clearing of pulmonary 
infiltrates.[9] No short-term adverse events were reported.
Immunoglobulins
It is possible that high-dose intravenous immunoglobulin may have a 
beneficial effect in the hyperinflammatory phase.[10]
In the second phase of the illness where pulmonary infiltrates 
and hypoxaemia begin to occur, it is reasonable to try agents such 
as chloroquine, azithromycin, colchicine and zinc as combinations 
or as single agents. The objective would be to use anti-inflammatory 
therapies early in the pulmonary phase to reduce progression to 
severe disease.
Does remdesivir meet accepted 
standards?
Remdesivir is a specific antiviral agent, first identified to have 
antiviral properties in the Ebola virus outbreak in West Africa in 
2016.[11] Unfortunately, it was found to have limited clinical efficacy 
and was abandoned as a useful therapy.[12]
Remdesivir has subsequently made its way back into the medical 
world as we seek a solution to the COVID-19 crisis. Unfortunately, 
in this pandemic, very few therapies touted as potentially useful have 
been able to stand the test of randomised controlled trial investigation. 
Despite early reports on drugs such as hydroxychloroquine and 
azithromycin, these agents have demonstrated limited efficacy.
We would like to state on record that remdesivir is an expensive 
therapy that has not met the criteria for scientific validity. The 
mortality difference compared with placebo (8.0% v. 11.6%) – the 
ultimate test of scientific credibility – did not reach statistical 
significance (p=0.059). The median time to recovery was 11 days with 
remdesivir compared with 15 days for placebo, representing a 31% 
faster time (p≤0.001). This was reported as the primary endpoint.
It is surprising that the FDA has approved a relatively ineffective 
therapy for emergency use before publication of the actual trial. Their 
doing so is of particular concern to those of us in disadvantaged 
communities. The FDA is suggesting that remdesivir should be 
recommended and widely utilised, but it would be unaffordable in 
resource-limited settings, potentially diverting funding away from 
equally important areas that can ill afford the financial deprivation. 
It is essential that we develop effective antiviral therapies, but 
the endpoint should be a mortality difference rather than a small 
reduction in recovery time.
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